April 2009
Worldwide Biotech;Apr2009, Vol. 21 Issue 4, p7
Trade Publication
The article reports on a research and development partnership between biotechnology and research services company Epistem PLC and Novartis to identify new drug targets and therapeutics across a variety of disease areas. The partnership would integrate Epistem's stem cell expertise and drug discovery program with Novartis's insights into disease pathways & bioinformatics. Terms of the agreement prompt Novartis to pay Epistem $4.0 million and provide research funding for two years.


Related Articles

  • Epistem, Novartis to Explore Training Existing Stem Cells. Moran, Nuala // BioWorld Today;3/3/2009, Vol. 20 Issue 40, p1 

    The article reports on research and development agreement signed by epithelial stem cell company Epistem plc with Novartis AG to explore existing stem cells training. Under the agreement, Novartis will pay $45 million for the registration of products to be developed by Epistem. Novartis will...

  • Epistem, Novartis to explore training existing stem cells. MORAN, NUALA // Medical Device Daily;3/5/2009, Vol. 13 Issue 42, p3 

    The article reports on a research and development (R&D) partnership between epithelial stem cell specialist Epistem and Novartis which involves the latter paying $45 million in milestones up to registration for each product emerging from the collection of 266 gene targets that is the subject of...

  • SomaLogic announces agreement with leading global pharma company to accelerate R&D Powerful proteomic technology to be applied to biomarker discovery, target discovery and validation, and companion diagnostics.  // Biomedical Market Newsletter;10/24/2011, Vol. 21, p544 

    The article reports on the multi-year research agreement between SomaLogic Inc. and Novartis that would allow the use of SomaLogic's proprietary proteomics technology to speed up the drug discovery and development efforts of Novartis. Larry Gold of SomaLogic asserts that the agreement provides...

  • EMBRYONIC STEM CELLS IN DRUG DISCOVERY. McNeish, John // Nature Reviews Drug Discovery;Jan2004, Vol. 3 Issue 1, p70 

    The completed sequencing of the human genome has identified numerous potential drug targets, which are expected to deliver the next generation of new medicines. However, for drug companies to realize this opportunity, they must rely on improved prognostic applications of high-throughput...

  • Power of Defined Groups. Dickey, Chris // Drug Discovery & Development;Aug2003, Vol. 6 Issue 8, p11 

    Editorial. Focuses on the tyrosine kinase inhibitor Gleevec, developed by Novartis AG for cancer. Clinical trials of the drug; Commercial viability of Gleevec.

  • MS Therapy Shows Sustained Benefits.  // Drug Discovery & Development;May2008, Vol. 11 Issue 5, p30 

    The article evaluates the oral therapy FTY720 (fingolimod) from Novartis AG.

  • Panel OKs Money for Stem Cell Clinical Trials. Chambers, Heather // San Diego Business Journal;3/15/2010, Vol. 31 Issue 11, p8 

    The article reports that the governing board for the state's three billion dollars stem cell institute approved the funding for the development of new stem cell therapies in San Diego, California.

  • Epistem, Novartis to Explore Training Existing Stem Cells. Moran, Nuala // BioWorld International;3/4/2009, Vol. 14 Issue 9, p1 

    The article reports on the research and development agreement signed by Epistem plc with Novartis AG for stem cells. Novartis is making a $4 million up-front payment in addition to funding all research and development for the next two years. After the announcement of the deal, the shares of...

  • Epistem, Novartis to Explore Stem Cells.  // Bioworld Week;3/9/2009, Vol. 17 Issue 10, p3 

    The article reports that Epistem PLC has agreed to the payment of $45 million in milestones by Novartis AG for the registration of its product in Switzerland. It states that Novartis will make a $4 million up-front payment for Epistem for the collection of 266 gene which are subject for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics